Abstract:<p>Epilepsy is a chronic neurologic disorder that affects over 70 million people worldwide. Despite the availability of over 20 antiseizure drugs (ASDs) for symptomatic treatment of epileptic seizures, about one-third of patients with epilepsy have seizures refractory to pharmacotherapy. Patients with such drug-resistant epilepsy (DRE) have increased risks of premature death, injuries, psychosocial dysfunction, and a reduced quality of life, so development of more effective therapies is an urgent clinical need. However, the various types of epilepsy and seizures and the complex temporal patterns of refractoriness complicate the issue. Furthermore, the underlying mechanisms of DRE are not fully understood, though recent work has begun to shape our understanding more clearly. Experimental models of DRE offer opportunities to discover, characterize, and challenge putative mechanisms of drug resistance. Furthermore, such preclinical models are important in developing therapies that may overcome drug resistance. Here, we will review the current understanding of the molecular, genetic, and structural mechanisms of ASD resistance and discuss how to overcome this problem. Encouragingly, better elucidation of the pathophysiological mechanisms underpinning epilepsies and drug resistance by concerted preclinical and clinical efforts have recently enabled a revised approach to the development of more promising therapies, including numerous potential etiology-specific drugs ("precision medicine") for severe pediatric (monogenetic) epilepsies and novel multitargeted ASDs for acquired partial epilepsies, suggesting that the long hoped-for breakthrough in therapy for as-yet ASD-resistant patients is a feasible goal.</p>Significance Statement<p>Drug resistance provides a major challenge in epilepsy management. Here, we will review the current understanding of the molecular, genetic, and structural mechanisms of drug resistance in epilepsy and discuss how the problem might be overcome.</p>

Drug-resistant epilepsy: Definition, pathophysiology, and management

Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options

Recent Advances in Pharmacologic Treatments of Drug-Resistant Epilepsy: Breakthrough in Sight

Insight into Drug Resistance in Status Epilepticus: Evidence from Animal Models

Current Principles in the Management of Drug-Resistant Epilepsy

A Revolutionary Approach for Combating Efflux Transporter-mediated Resistant Epilepsy: Advanced Drug Delivery Systems

The Pharmacoresistant Epilepsy: An Overview on Existant and New Emerging Therapies

Drug-Resistant Epilepsy and Gut-Brain Axis: an Overview of a New Strategy for Treatment

Current Trends and Hotspots in Drug-Resistant Epilepsy Research: Insights from a Bibliometric Analysis.

Risk Factors for Drug-Resistant Epilepsy A Systematic Review and Meta-Analysis

Drug-resistant epilepsy in Indian children at a tertiary-care public hospital

The Problem of the Drug-Resistant Epilepsies

Difficulties in Treatment and Management of Epilepsy and Challenges in New Drug Development

Refractory Epilepsy: A Clinically Oriented Review

Impact of regulatory safety warnings and restrictions on drug treatment of epilepsy

Refractory Epilepsy: Clinical Overview

Neuroprotective Efficacy and Complementary Treatment with Medicinal Herbs: A Comprehensive Review of Recent Therapeutic Approaches in Epilepsy Management

Refractory epilepsy: mechanisms and solutions

Definition of drug‐resistant epilepsy: A reappraisal based on epilepsy types

Drug-Resistant Epilepsy: Experience From a Tertiary Care Center in Saudi Arabia

Current and future pharmacotherapy options for drug-resistant epilepsy